NCT03425552
A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment
Phase: Phase 1/2
Role: Lead Sponsor
Start: Mar 11, 2018
Completion: May 2, 2019